DE3751870T2 - REKOMBINANTES PLASMID, UMFASSEND EIN FRAGMENT EINES DNA-SEGMENTES, DAS FüR EIN 47 KDA OBERFLäCHENIMMUNOGEN VON TREPONEMA PALLIDUM KODIERT - Google Patents
REKOMBINANTES PLASMID, UMFASSEND EIN FRAGMENT EINES DNA-SEGMENTES, DAS FüR EIN 47 KDA OBERFLäCHENIMMUNOGEN VON TREPONEMA PALLIDUM KODIERTInfo
- Publication number
- DE3751870T2 DE3751870T2 DE3751870T DE3751870T DE3751870T2 DE 3751870 T2 DE3751870 T2 DE 3751870T2 DE 3751870 T DE3751870 T DE 3751870T DE 3751870 T DE3751870 T DE 3751870T DE 3751870 T2 DE3751870 T2 DE 3751870T2
- Authority
- DE
- Germany
- Prior art keywords
- pallidum
- kda
- immunogen
- pages
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000589884 Treponema pallidum Species 0.000 title claims abstract description 162
- 239000012634 fragment Substances 0.000 title claims description 49
- 230000002163 immunogen Effects 0.000 claims abstract description 93
- 108020004414 DNA Proteins 0.000 claims abstract description 72
- 241000588724 Escherichia coli Species 0.000 claims abstract description 48
- 239000013612 plasmid Substances 0.000 claims abstract description 45
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 230000000813 microbial effect Effects 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 24
- 238000009396 hybridization Methods 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 16
- 230000001717 pathogenic effect Effects 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 238000000151 deposition Methods 0.000 claims 1
- 102000036639 antigens Human genes 0.000 abstract description 74
- 108091007433 antigens Proteins 0.000 abstract description 74
- 239000000427 antigen Substances 0.000 abstract description 73
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 38
- 210000002966 serum Anatomy 0.000 abstract description 19
- 238000002105 Southern blotting Methods 0.000 abstract description 10
- 238000003156 radioimmunoprecipitation Methods 0.000 abstract description 9
- 238000001262 western blot Methods 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000037230 mobility Effects 0.000 abstract description 4
- 238000012742 biochemical analysis Methods 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 230000002865 vaccinogenic effect Effects 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 2
- 241000894007 species Species 0.000 abstract description 2
- 102000053602 DNA Human genes 0.000 description 63
- 239000000523 sample Substances 0.000 description 18
- 239000000499 gel Substances 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 239000013598 vector Substances 0.000 description 11
- 108020004511 Recombinant DNA Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 208000006379 syphilis Diseases 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000028996 humoral immune response Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 241001646716 Escherichia coli K-12 Species 0.000 description 3
- 201000000860 Secondary syphilis Diseases 0.000 description 3
- 241000589886 Treponema Species 0.000 description 3
- 241000589892 Treponema denticola Species 0.000 description 3
- 241000984746 Treponema vincentii Species 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 2
- 241000589910 Treponema phagedenis Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 201000009482 yaws Diseases 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710092702 47 kDa protein Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010053025 Endemic syphilis Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101001125837 Escherichia coli (strain K12) Pilin Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000025884 Treponema infectious disease Diseases 0.000 description 1
- 241000520846 Treponema paraluiscuniculi Species 0.000 description 1
- 208000035055 Treponemal Infections Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000003796 chancre Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000009090 primary syphilis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/913,724 US4868118A (en) | 1986-09-30 | 1986-09-30 | Cloning and expression of the 47-kilodalton antigen of treponema pallidum |
| PCT/US1987/002403 WO1988002403A1 (en) | 1986-09-30 | 1987-09-21 | Cloning and expression of the 47-kilodalton antigen of treponema pallidum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3751870D1 DE3751870D1 (de) | 1996-09-19 |
| DE3751870T2 true DE3751870T2 (de) | 1997-03-20 |
Family
ID=25433526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3751870T Expired - Lifetime DE3751870T2 (de) | 1986-09-30 | 1987-09-21 | REKOMBINANTES PLASMID, UMFASSEND EIN FRAGMENT EINES DNA-SEGMENTES, DAS FüR EIN 47 KDA OBERFLäCHENIMMUNOGEN VON TREPONEMA PALLIDUM KODIERT |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4868118A (enExample) |
| EP (1) | EP0324774B1 (enExample) |
| JP (1) | JPH02500403A (enExample) |
| AT (1) | ATE141325T1 (enExample) |
| AU (1) | AU8021487A (enExample) |
| CA (1) | CA1336692C (enExample) |
| CH (1) | CH676606A5 (enExample) |
| DE (1) | DE3751870T2 (enExample) |
| DK (1) | DK293988A (enExample) |
| IL (1) | IL84006A (enExample) |
| WO (1) | WO1988002403A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681934A (en) * | 1986-09-30 | 1997-10-28 | Board Of Regents, The University Of Texas System | 47-kilodalton antigen of Treponema pallidum |
| US4956230A (en) * | 1987-04-13 | 1990-09-11 | Minnesota Mining And Manufacturing Company | Ink receptive transparency sheet |
| WO1990015132A2 (en) * | 1989-05-24 | 1990-12-13 | Syntro Corporation | Cloned treponema hyodysenteriae endoflagellar antigen |
| US5474900A (en) * | 1990-03-16 | 1995-12-12 | Sekisui Chemical Co., Ltd. | Process for preparing purified syphilis antigen from Treponema palljdum |
| FR2707168B1 (fr) * | 1993-07-08 | 1995-08-18 | Rhone Merieux | Vaccin contre la dysenterie hémorragique du porc et ensemble de vaccination y relatif. |
| RU2103362C1 (ru) * | 1995-07-14 | 1998-01-27 | Товарищество с ограниченной ответственностью Биотехнологическая компания "БИОСЕРВИС" | Набор для обнаружения антител к бледной спирохете treponema pallidum, рекомбинантный полипептидный антиген treponema pallidum 15 кда, рекомбинантный полипептидный антиген treponema pallidum 17 кда и рекомбинантный полипептидный антиген treponema pallidum tmp a |
| DE19536166C1 (de) * | 1995-09-29 | 1997-03-06 | Siegfried Dr Krell | Verfahren zur Bestimmung von Antikörpern gegen Treponema pallidum (Syphilis) |
| US6020128A (en) * | 1997-06-10 | 2000-02-01 | United States Of Ameria | DNA polymerase from Treponema pallidum |
| WO1999053099A1 (en) * | 1998-04-10 | 1999-10-21 | University Of Washington | Recombinant proteins of treponema pallidum and their use for a syphilis vaccine |
| US6667038B1 (en) * | 1999-04-21 | 2003-12-23 | Boston Medical Center Corp. | Prevention, diagnosis and treatment of lyme disease |
| CA2794710C (en) | 2010-03-31 | 2018-05-08 | Sekisui Medical Co., Ltd. | Reagent for assaying anti-treponema pallidum antibody |
| JP5911889B2 (ja) | 2011-01-13 | 2016-04-27 | オーソ−クリニカル・ダイアグノスティックス・インコーポレイテッドＯｒｔｈｏ−Ｃｌｉｎｉｃａｌ Ｄｉａｇｎｏｓｔｉｃｓ， Ｉｎｃ． | 梅毒トレポネーマトリプレット抗原 |
| CN112772552B (zh) * | 2020-12-31 | 2022-05-17 | 青岛胶南康大饲料有限公司 | 肉兔饲养方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE427516B (sv) * | 1981-11-10 | 1983-04-11 | Ericsson Telefon Ab L M | Sett och anordning for att korrigera distortion i en pa elektronisk veg upptecknad av bildelement lengs linjer uppbyggd bild |
| US4514498A (en) * | 1982-05-26 | 1985-04-30 | The Board Of Regents, The University Of Texas System | Hybrid cell lines producing monoclonal antibodies directed against Treponema |
| JPS59502131A (ja) * | 1982-11-12 | 1984-12-27 | ザ リ−ジエンツ オブ ユニバ−シテイ オブ カリフオルニア | 組換えｄｎａ誘導型梅毒トレポネ−マ抗原 |
-
1986
- 1986-09-30 US US06/913,724 patent/US4868118A/en not_active Expired - Lifetime
-
1987
- 1987-09-21 WO PCT/US1987/002403 patent/WO1988002403A1/en not_active Ceased
- 1987-09-21 EP EP87906542A patent/EP0324774B1/en not_active Expired - Lifetime
- 1987-09-21 AU AU80214/87A patent/AU8021487A/en not_active Abandoned
- 1987-09-21 DE DE3751870T patent/DE3751870T2/de not_active Expired - Lifetime
- 1987-09-21 JP JP62505911A patent/JPH02500403A/ja active Pending
- 1987-09-21 AT AT87906542T patent/ATE141325T1/de not_active IP Right Cessation
- 1987-09-21 CH CH2160/88A patent/CH676606A5/de not_active IP Right Cessation
- 1987-09-23 CA CA000547633A patent/CA1336692C/en not_active Expired - Lifetime
- 1987-09-27 IL IL84006A patent/IL84006A/xx not_active IP Right Cessation
-
1988
- 1988-05-30 DK DK293988A patent/DK293988A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US4868118A (en) | 1989-09-19 |
| JPH02500403A (ja) | 1990-02-15 |
| EP0324774A1 (en) | 1989-07-26 |
| CA1336692C (en) | 1995-08-15 |
| AU8021487A (en) | 1988-04-21 |
| WO1988002403A1 (en) | 1988-04-07 |
| DK293988D0 (da) | 1988-05-30 |
| CH676606A5 (enExample) | 1991-02-15 |
| DK293988A (da) | 1988-07-14 |
| IL84006A0 (en) | 1988-02-29 |
| ATE141325T1 (de) | 1996-08-15 |
| IL84006A (en) | 1992-11-15 |
| EP0324774B1 (en) | 1996-08-14 |
| DE3751870D1 (de) | 1996-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0506868B2 (de) | Immunologisch aktive proteine von borrelia burgdorferi, zusammenhängende testkits und impfstoff | |
| DE69232956T2 (de) | Verbesserungen der diagnose und der prophylaxe von borrelia burgdorferi | |
| DE3751870T2 (de) | REKOMBINANTES PLASMID, UMFASSEND EIN FRAGMENT EINES DNA-SEGMENTES, DAS FüR EIN 47 KDA OBERFLäCHENIMMUNOGEN VON TREPONEMA PALLIDUM KODIERT | |
| Vanrompay et al. | Characterization of avian Chlamydia psittaci strains using omp1 restriction mapping and serovar-specific monoclonal antibodies | |
| EP0643974B1 (de) | Impfstoff gegen die Lyme-Krankheit | |
| DE69012318T2 (de) | Impfstoffe gegen hämophilus influenzae. | |
| DE69220042T3 (de) | Mycobakterium polypeptide und dafür kodierende nukleinsäuren zur diagnose und kontrolle von tuberkulose | |
| Coleman et al. | Identification and characterization of an endoflagellar antigen of Borrelia burgdorferi. | |
| DE3650571T2 (de) | Hauptprotein der Aussenmembran von Chlamydia | |
| DE69033453T2 (de) | Rekombinante Polypeptide und Peptide, dafür kodierende Nukleinsäuren und ihre Verwendung in der Tuberkulose-Diagnose | |
| Norgard et al. | Cloning and expression of the major 47-kilodalton surface immunogen of Treponema pallidum in Escherichia coli | |
| DE69122240T2 (de) | Antigen-wirkende proteine von borrelia burgdorferi | |
| DE69214277T2 (de) | Dna-sequenzen, die für die virulente eigenschaft von -i(streptococcus suis) kodieren, und teile davon, polypeptide und antikörper die sich davon ableiten und deren verwendung für diagnose und prophylaxe der infektion mit streptococcus suis in säugetieren, insbesondere in menschen | |
| DE69408135T2 (de) | Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene | |
| DE69231519T2 (de) | Polypeptide aus micobakterium paratuberculosis | |
| DE3856240T2 (de) | Herstellung der p1 proteine und impfstoffe gegen gonorrhöe | |
| EP0918865B1 (de) | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe | |
| DE69016671T2 (de) | Rekombinanter impfstoff gegen schweinepleuropneumonie. | |
| US5369005A (en) | Method for mycoplasma detection in a biological sample | |
| DE69331377T2 (de) | Verfahren und zusammensetzungen zur diagnose der katzenkratzkrankheit und der bakteriellen angiomatose | |
| DE68916424T2 (de) | Pasteurella-impfstoff. | |
| DE69535156T2 (de) | Verfahren und zusammensetzungen zur diagnose von rochalimaea henselae und rochalimaea quintana infektion | |
| DE68928933T2 (de) | Faser-hemagglutinin von b. pertussis | |
| DE69733067T2 (de) | Behandlung und bestimmung von gram-positiven kokkeninfektionen | |
| DE3942728C1 (en) | New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |